Understanding cancer-induced cachexia: Imaging the flame and its fuel

Current Opinion in Supportive and Palliative Care

Volumn 5, Issue 4, 2011, Pages 327-333

  Penet, Marie France ^a   Winnard Jr , Paul T ^a   Jacobs, Michael A ^a,b   Bhujwalla, Zaver M ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cachexia; Clinical translation; Metabolism; Molecular and functional imaging

Indexed keywords

CACHEXIA; CARBOHYDRATE DIET; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; INSTRUMENTATION; LIPID METABOLISM; METABOLISM; MOLECULAR IMAGING; NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL STATUS; PATHOLOGY; REVIEW; RISK FACTOR;

CACHEXIA; DIETARY CARBOHYDRATES; HUMANS; LIPID METABOLISM; MAGNETIC RESONANCE IMAGING; MOLECULAR IMAGING; NEOPLASMS; NUTRITIONAL STATUS; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84856886673     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e32834c49ba     Document Type: Review

References (34)

1. Loberg RD, Bradley DA, Tomlins SA, et al. The lethal phenotype of cancer: The molecular basis of death due to malignancy. CA Cancer J Clin 2007; 57:225-241. (Pubitemid 47312082)
2. Inui A. Cancer anorexia-cachexia syndrome: Current issues in research and management. CA Cancer J Clin 2002; 52:72-91. (Pubitemid 34256834)
3. Berry J, Baum C. Reversal of COPD-associated weight loss. Drugs 2004; 64:1041-1052.
4. Mak RH CW, Cone RD, Marks DL. Orexigenic and anorexigenic mechanisms in the control of nutrition in chronic kidney disease. Pediatr Nephrol 2005; 20:427-431. (Pubitemid 40309955)
5. Ferrigno D, Buccheri G. Anthropometric measurements in nonsmall cell lung cancer. Supp Care Cancer 2001; 9:522-527. (Pubitemid 32927883)
6. Tan BH FK. Cachexia: Prevalence and impact in medicine. Curr Opin Clin Nutr Metab Care 2008; 11:400-407.
7. Bosaeus I, Daneryd P, Svanberg E, Lundholm K. Dietary intake and resting energy expenditure in relation to weight loss in unselected cancer patients. Int J Cancer 2001; 93:380-383. (Pubitemid 32592057)
8. Evans WK, Makuch R, Clamon GH, et al. Limited impact of total parenteral nutrition on nutritional status during treatment for small cell lung cancer. Cancer Res 1985; 45:3347-3353. (Pubitemid 15007216)
9. Lowell BB, Ruderman NB, Goodman MN. Evidence that lysosomes are not involved in the degradation of myofibrillar proteins in rat skeletal muscle. Biochem J 1986; 234:237-240. (Pubitemid 16053683)
10. Simons JP, Schols AM, Hoefnagels JM, et al. Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, non hormone sensitive cancer. Cancer Res 1998; 82:553-560. (Pubitemid 28112995)
11. Rowland KM Jr, Loprinzi CL, Shaw EG, et al. Randomised double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/ placebo in extensive-stage small-cell lung cancer: A North Central Cancer Treatment Group Study. J Clin Oncol 1996; 14:135-141. (Pubitemid 26020006)
12. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: An international consensus. Lancet Oncol 2011; 12:489-495. This review summarizes the most recent definition, diagnostic criteria, and classification of cancer cachexia to improve clinical management, trial design, education and policy.
13. Tisdale MJ. Molecular pathways leading to cancer cachexia. Physiology (Bethesda) 2005; 20:340-348. (Pubitemid 41457399)
14. Esper DH, Harb WA. The cancer cachexia syndrome: A review of metabolic and clinical manifestations. Nutr Clin Pract 2005; 20:369-376. (Pubitemid 47050807)
15. Couch M, Lai V, Cannon T, et al. Cancer cachexia syndrome in head and neck cancer patients. Part I: Diagnosis, impact on quality of life and survival, and treatment. Head Neck 2007; 29:401-411. (Pubitemid 46623505)
16. Glunde K, Pathak AP, Bhujwalla ZM. Molecular-functional imaging of cancer: To image and imagine. Trends Mol Med 2007; 13:287-297. (Pubitemid 47017002)
17. Jacobs MA, Ouwerkerk R, Wolff AC, et al. Monitoring of neoadjuvant chemotherapy using multiparametric, (23)Na sodium MR, and multimodality (PET/ CT/MRI) imaging in locally advanced breast cancer. Breast Cancer Res Treat 2011; 128:119-126. This clinical study provides examples of multimodal imaging techniques applied to breast cancer that can, in the future, be applied to better understand cachexia.
18. Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev 2009; 89:381-410.
19. O'Connell TM, Ardeshirpour F, Asher SA, et al. Metabolomic analysis of cancer cachexia reveals distinct lipid and glucose alterations. Metabolomics 2008; 4:216-225.
20. Constantinou C, Fontes de Oliveira CC, Mintzopoulos D, et al. Nuclear magnetic resonance in conjunction with functional genomics suggests mitochondrial dysfunction in a murine model of cancer cachexia. Int J Mol Med 2011; 27:15-24. In these preclinical studies in vivo 31P MRS combined with genome transcriptome analysis revealed the implication of mitochondrial dysfunction in cachexia, showing the importance of combining multiple techniques to better characterize the syndrome.
21. Schneeberger AL, Thompson RT, Driedger AA, et al. Effect of cancer on the in vivo energy state of rat liver and skeletal muscle. Cancer Res 1989; 49:1160-1164. (Pubitemid 19074829)
22. Gehman KE, Inculet RI, Brauer M, et al. Early detection of cancer cachexia in the rat using 31P magnetic resonance spectroscopy of the liver and a fructose stress test. NMR Biomed 1996; 9:271-275.
23. Das SK, Eder S, Schauer S, et al. Adipose triglyceride lipase contributes to cancer-associated cachexia. Science 2011; 833:233-238.
24. Tan BH, Birdsell LA, Martin L, et al. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 2009; 15:6973-6979.
25. Prado CM, Baracos VE, McCargar LJ, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 2009; 15:2920-2926.
26. Del Fabbro E. More is better: A multimodality approach to cancer cachexia. Oncologist 2010; 15:119-121.
27. Bachmann J, Ketterer K, Marsch C, et al. Pancreatic cancer related cachexia: Influence on metabolism and correlation to weight loss and pulmonary function. BMC Cancer 2009; 9:255.
28. Mantovani G, Maccio A, Madeddu C, et al. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist 2010; 15:200-211. CT measurements, amongst other clinical parameters, were analyzed to assess the efficacy of different treatments in cachectic patients.
29. Weber MA, Krakowski-Roosen H, Schroder L, et al. Morphology, metabolism, microcirculation, and strength of skeletal muscles in cancer-related cachexia. Acta Oncol 2009; 48:116-124.
30. Gray C, MacGillivray TJ, Eeley C, et al. Magnetic resonance imaging with kmeans clustering objectively measures whole muscle volume compartments in sarcopenia/cancer cachexia. Clin Nutr 2011; 30:106-111. These clinical studies show the importance of using MRI techniques to assess how cachexia affects muscles not only by measuring their volume, but also by distinguishing between contractile and noncontractile components.
31. Raman V, Artemov D, Pathak AP, et al. Characterizing vascular parameters in hypoxic regions: A combined magnetic resonance and optical imaging study of a human prostate cancer model. Cancer Res 2006; 66:9929-9936. (Pubitemid 44672045)
32. Bhujwalla ZM, Artemov D, Ballesteros P, et al. Combined vascular and extracellular pH imaging of solid tumors. NMR Biomed 2002; 15:114-119. (Pubitemid 34213401)
33. Glunde K, Raman V, Mori N, Bhujwalla ZM. RNA interferencemediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. Cancer Res 2005; 65:11034-11043. (Pubitemid 41713374)
34. Narayana PA. Magnetic resonance spectroscopy in the monitoring of multiple sclerosis. J Neuroimaging 2005; 15 (4 Suppl):46S-57S. (Pubitemid 43010531)